📈 Jumpstart Signal Watchlist — October 30, 2026

🏢 What they do: Kenvue Inc. is a global consumer health company that makes and sells everyday health and personal care products. Its brands include Tylenol, Zyrtec, Listerine, Neutrogena, Aveeno, Johnson’s, and BAND-AID, spanning products for self-care, skin health and beauty, and essential health.
- 🎯 Current $19.31 is 21% below 3yr high $24.44 · ⏳ SMA200 $18.18 (current price $19.31 is above) · 💰 Market Cap $37.1B
- KVUE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 39/60
- 🏦 Low drawdown (13.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; ROE 17% (>15%); Low LT D/E 0.76 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 11/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (60) — BEARISH
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×2 ❌×1 ⚪️×2).
✅ Kenvue (KVUE) Surpasses Q3 Earnings Estimates — Zacks.
🤖 Zacks reports adjusted EPS of $0.29, above its $0.28 consensus estimate, although revenue slightly missed its estimate. The article also notes an unfavorable estimate-revisions trend and a Zacks Rank of Sell, which temper the earnings beat.
✅ Kenvue: Q3 Earnings Snapshot — Associated Press.
🤖 Kenvue’s adjusted earnings of $0.29 per share beat the surveyed analyst estimate of $0.28, while revenue of $3.89 billion matched forecasts. The earnings beat is a modest positive.
❌ Kenvue misses third-quarter profit expectations — Investing.com.
🤖 Kenvue’s adjusted EPS of $0.29 fell short of the $0.37 analyst consensus, despite revenue growth and revenue slightly exceeding expectations. The company also did not provide forward-looking guidance because of its pending transaction with Kimberly-Clark.
⚪️ Kenvue Reports Third Quarter 2026 Results — Business Wire.
🤖 Kenvue reported 3.2% year-over-year sales growth and adjusted EPS of $0.29, up from $0.28 a year earlier. The results show modest growth, though the separate report of a miss against analyst profit expectations tempers the picture.
⚪️ Kenvue set to be delisted on Monday before open after Kimberly-Clark deal — Seeking Alpha.
🤖 Kenvue is expected to be delisted from the NYSE as its $40 billion sale to Kimberly-Clark closes. This is a transaction-related change for shareholders rather than a standalone operating catalyst.
🍭 Bonus (B): 0/10 — Perfumes & Cosmetics

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.30 is 11% below 3yr high $12.66 · ⏳ SMA200 $9.45 (current price $11.30 is above) · 💰 Market Cap $1.9B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Vir Biotechnology stock hits 52-week high at $12.02 — Investing.com.
🤖 The article reports that Vir shares reached a 52-week high and notes recent financial improvement, including a collaboration payment that lifted cash reserves above $1 billion. It also cites an analyst price-target increase and Buy rating.
✅ Vir Biotechnology appoints cancer expert to board — Investing.com.
🤖 Vir appointed cancer expert Suzanne Topalian to its board, adding relevant oncology expertise as the company advances its cancer-treatment programs.
✅ Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal? — Yahoo Finance.
🤖 The article highlights Vir’s Gilead oncology collaboration, including upfront and potential milestone payments, alongside recent share-price momentum. It presents a bullish valuation narrative, while noting that pipeline and regulatory risks remain.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Aveanna Healthcare provides in-home nursing and therapy, home health and hospice care, and medical supplies such as enteral nutrition products. Its services support children and adults with complex medical needs.
- 🎯 Current $13.16 is 8% below 3yr high $14.38 · ⏳ SMA200 $9.28 (current price $13.16 is above) · 💰 Market Cap $2.9B
- AVAH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 38% (>20%); ROE 96% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.27 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×4; showing 3 of 4).
✅ Aveanna Healthcare Holdings Inc. (AVAH) Stock Could Be Cheap On Earnings — Yahoo Finance.
🤖 The article argues that Aveanna’s shares may be undervalued relative to its earnings and a fair-value estimate. It is valuation commentary rather than a new company announcement.
🤖 The article describes Aveanna as trading at a discount to sector and peer earnings multiples and says its valuation framework indicates potential undervaluation. This is a favorable valuation view, not a new operating update.
✅ Is Aveanna Healthcare Holdings (AVAH) Still Below Fair Value Following Its Zacks Upgrade? — Yahoo Finance.
🤖 The article notes a Zacks Rank of #2 and an increase in full-year earnings estimates, and says the shares trade below a cited fair-value estimate. Those factors suggest a favorable earnings outlook and potential upside.
✅ Aveanna Healthcare Holdings Inc. (AVAH) — Yahoo Finance.
🤖 The search result lists an announcement of second-quarter financial results and revised 2026 guidance, but provides no details about the results or the direction of the guidance. The available information is insufficient to assess the catalyst confidently.
🍭 Bonus (B): 0/10 — Home Health Care Services

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $40.38 is 2% below 3yr high $41.25 · ⏳ SMA200 $28.44 (current price $40.38 is above) · 💰 Market Cap $5.1B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (6.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (10.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Concentra Group Holdings stock hits all-time high at 41.01 USD — Investing.com.
🤖 The article reports CON reaching an all-time high and cites favorable developments, including stronger operating performance and credit-rating upgrades. The article’s publication date is October 29, 2026; its later update date does not change that.
✅ Concentra Group Holdings Parent (NYSE:CON) Sets New 1-Year High - What's Next? — MarketBeat.
🤖 The article reports CON setting a new one-year high and notes a consensus Buy rating. Its publication date is October 28, 2026; the later update date does not change that.
✅ Stephens Initiates Concentra Group Holdings Parent at Overweight With $45 Price Target — Yahoo Finance.
🤖 Stephens initiated coverage with an Overweight rating and a $45 price target, signaling a favorable analyst view. The article is dated October 20, 2026.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: JAKKS Pacific designs, develops, markets, and distributes toys and consumer products, including dolls, action figures, playsets, and licensed-character products. It also sells costumes and related accessories for Halloween and everyday dress-up.
- 🎯 Current $31.39 is 14% below 3yr high $36.45 · ⏳ SMA200 $23.02 (current price $31.39 is above) · 💰 Market Cap $360M
- JAKK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (11.5% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 43% (>20%); Revenue growth 20% (>15%); Low LT D/E 0.25 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.5%)
- 🔔 Strong above EMA50 (14.2%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ JAKKS Pacific Reports Third Quarter 2026 Financial Results — GlobeNewswire.
🤖 Third-quarter net sales rose 20% year over year to $254.2 million, while operating income increased 27% to $37.4 million. The strong growth in sales and profitability is positive for the stock.
✅ JAKKS Pacific earnings beat by $0.34, revenue topped estimates — Investing.com.
🤖 Adjusted earnings of $2.68 per share exceeded the $2.34 estimate, and revenue of $254.2 million topped consensus. Beating both earnings and revenue expectations is a positive catalyst.
✅ What JAKKS Pacific (JAKK) Said on Its Q3 Earnings Call — Yahoo Finance.
🤖 The call highlighted 20% quarterly sales growth, higher adjusted EBITDA and EPS, and a $0.25 quarterly dividend. International sales declined and product and freight costs remained pressures, but the overall results and growth were favorable.
🍭 Bonus (B): 0/10 — Games & Toys

🏢 What they do: Five9, Inc. provides cloud contact center software, including its Intelligent CX platform for managing customer interactions across voice and digital channels like chat, email, SMS, and social media. Its products also include AI, automation, analytics, and workforce optimization tools that help businesses run customer service and sales operations.
- 🎯 Current $36.34 is 58% below 3yr high $85.47 · ⏳ SMA200 $24.11 (current price $36.34 is above) · 💰 Market Cap $2.7B
- FIVN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 300% (>20%); Low LT D/E 0.25 (<1.0); PEG ratio 0.18 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×3; showing 4 of 5).
✅ Accelerating AI Revenue and Raised Full-Year Outlook Drive Five9’s (FIVN) Outperformance — Yahoo Finance.
🤖 The article reports accelerating subscription growth, sharply higher AI-related revenue, a significant multi-year enterprise contract, and a raised full-year AI revenue growth outlook. These developments suggest stronger demand and improved growth expectations.
✅ Five9 Named a Leader in the 2026 Gartner® Magic Quadrant™ for Contact Center as a Service for the Ninth Time — Yahoo Finance.
🤖 Five9 was recognized as a Leader for the ninth time, based on its completeness of vision and ability to execute. The recognition may reinforce the company’s competitive standing in the contact-center software market.
⚪️ Wells Fargo Maintains Equal-Weight on Five9, Raises Price Target to $36 — Benzinga.
🤖 Wells Fargo raised its price target while maintaining an Equal-Weight rating. The higher target is constructive, but the unchanged rating indicates a balanced overall view.
⚪️ Five9 (FIVN) Stock Looks About Right On Fresh Gartner Leader Recognition — Yahoo Finance.
🤖 The article discusses Five9’s Gartner recognition and strong year-to-date share performance, while noting that the stock’s valuation is above broader software and peer-group multiples. It presents the recognition as supportive but questions how much optimism is already reflected in the price.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: GigaCloud Technology Inc. (GCT) operates a B2B e-commerce marketplace specializing in large-parcel merchandise like furniture, appliances, and fitness equipment. It provides an end-to-end platform that connects manufacturers (primarily in Asia) with retailers in markets such as the US and Europe, handling product sourcing, logistics, global fulfillment across 39 facilities, sales, and delivery.
- 🎯 Current $58.38 is 4% below 3yr high $60.63 · ⏳ SMA200 $44.08 (current price $58.38 is above) · 💰 Market Cap $544M
- GCT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 27% (>20%); Revenue growth 28% (>15%); ROE 29% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ GigaCloud Technology Inc Ranks Among Top 15 on Fortune’s Fastest Growing Companies™ 2026 and TIME’s America’s Growth Leaders 2027 Lists — GlobeNewswire.
🤖 GigaCloud ranked No. 13 on Fortune’s fastest-growing companies list and No. 12 on TIME’s America’s Growth Leaders list. The recognition highlights the company’s growth and financial performance, though it is not a new financial result or guidance update.
✅ GigaCloud Technology (NASDAQ:GCT) Sets New 52-Week High - Time to Buy? — MarketBeat.
🤖 The article reports GCT reached a new 52-week high and cites recent analyst upgrades and a Strong Buy consensus. Its earnings figures refer to the company’s earlier August report, not new results in this article.
❌ Can GigaCloud Technology (GCT) Stay Below Fair Value On Cash Flow? — Yahoo Finance.
🤖 The article discusses GigaCloud’s cash flow and marketplace growth but also flags an investigation into possible fiduciary breaches by officers and directors. The potential governance and litigation costs create a negative risk overhang.
🍭 Bonus (B): 0/10 — Catalog & Mail-Order

🏢 What they do: ABM Industries provides facility management, engineering, and infrastructure services for businesses and institutions. Its services include commercial cleaning, building maintenance, HVAC and electrical work, energy solutions, landscaping, parking, and security.
- 🎯 Current $53.48 is 9% below 3yr high $58.61 · ⏳ SMA200 $44.84 (current price $53.48 is above) · 💰 Market Cap $3.1B
- ABM shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (6.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 25% (>20%); Low LT D/E 0.97 (<1.0); PEG ratio 0.76 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ ABM Industries (NYSE:ABM) Reaches New 12-Month High - Here's What Happened — MarketBeat.
🤖 The article notes ABM shares reached a 12-month high and cites recent quarterly results that beat EPS estimates, alongside the company’s fiscal 2026 guidance. The share-price milestone and earnings beat are positive signals, though the article also reports a consensus Hold rating.
✅ Abm Industries stock hits 52-week high at 54.68 USD — Investing.com.
🤖 ABM shares reached a 52-week high. The article also recaps quarterly results that met expectations and a higher UBS price target, although UBS maintained a Neutral rating.
⚪️ ABM Announces Executive Leadership Changes — GlobeNewswire.
🤖 ABM announced leadership changes effective November 1, including the COO’s planned retirement and new presidents for two business areas. The company described the changes as intended to support continued growth, but the announcement did not provide financial guidance or quantify an expected business impact.
🍭 Bonus (B): 0/10 — Services to Dwellings